The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse 151
Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on
"Global Polycystic Ovarian Syndrome Treatment Market - Forecast
to 2026"
By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents,
Antidepressants, Anti-obesity), By Surgery (Ovarian Wedge Resection,
Laparoscopic Ovarian Drilling), By Region (North America, Asia Pacific, CSA,
Europe, and the Middle East and Africa); End-User Landscape, Company Market
Share Analysis & Competitor Analysis.
Key Market Insights
·
PCOS
(polycystic ovary syndrome) is a hormonal endocrine disease that causes to females
aged 15 to 49 years old.
·
The appearance
of lumps on the ovaries is a sign of this disease, which contributes to a
deficiency of the ovulation-initiating hormone in the women's body.
·
The appearance
of lumps on the ovaries is a sign of this disease, which contributes to a
deficiency of the ovulation-initiating hormone in the women's body.
·
OCPs are often
used to cure Polycystic ovary syndrome complications such as prolonged or
missing menstrual cycles, extreme menstrual cramps, Premenstrual syndrome
(PMS), and acne.
·
The
insulin-sensitizing agent segment is currently the main revenue source,
attributed to the high usage of insulin-sensitizing agents as the first drug
for the treatment of PCOS.
·
Increasing
obesity and overweight incidence are contributing to an increase in the number
of women diagnosed with PCOS.
·
An increase in the number of target populations, a
growing R&D sector, an increase in healthcare reforms, and technical
breakthroughs in the field of healthcare all contribute to industry growth in
the APAC region.
·
Allergan
plc, Pfizer Inc.,Bayer AG, AstraZeneca plc., Bristol-Myers Squibb Company,
Mylan N.V., Johnson and Johnson, Novartis AG, Teva Pharmaceutical Industries, and
SANOFI, among others, are major players inthe polycystic ovarian syndrome
treatment market.
·
In January 2020, Evotec SE and Bayer AG
introduced a new five-year, multi-target agreement with Celmatix Inc. to
produce several therapeutic alternatives for the diagnosis of PCOS, which is anticipated to
accelerate the demand over the forecast timeframe
Browse the Report @https://www.globalmarketestimates.com/market-report/global-polycystic-ovarian-syndrome-treatment-market-3227
Drug Outlook (Revenue, USD Billion, 2021-2026)
·
Oral Contraceptives
·
Provera
·
Yasminell
·
Others
·
Antiandrogens
·
Clomid
·
Aldactone
·
Diane 35
·
Insulin-sensitizing Agent
·
Glucuphage
·
Kombiglyze
·
Others
·
Antidepressant
·
Anti-obesity
Surgery Outlook (Revenue, USD Billion, 2021-2026)
·
Ovarian Wedge Resection
·
Laparoscopic Ovarian Drilling
Regional Outlook
(Revenue, USD Billion, 2021-2026)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of APAC
Central
& South America
- Brazil
- Argentina
- Rest of CSA
Middle
East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
Contact:
Tracy Simon
Email address: tracy.simon@globalmarketestimates.com
Phone
Number: +16026667238
Website:
https://www.globalmarketestimates.com/
No comments:
Post a Comment